Carmat (ALCAR) - Total Liabilities

Latest as of December 2024: €93.56 Million EUR ≈ $109.38 Million USD

Based on the latest financial reports, Carmat (ALCAR) has total liabilities worth €93.56 Million EUR (≈ $109.38 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Carmat - Total Liabilities Trend (2009–2024)

This chart illustrates how Carmat's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Carmat to evaluate short-term liquidity relative to the company's equity base.

Carmat Competitors by Total Liabilities

The table below lists competitors of Carmat ranked by their total liabilities.

Company Country Total Liabilities
Loyal Solutions AS
ST:LOYAL
Sweden Skr53.19 Million
Daekyo Co Ltd
KO:019685
Korea ₩297.83 Billion
Lifecare AS
OL:LIFE
Norway Nkr92.13 Million
FIRST LITHIUM MINERALS
F:X28
Germany €531.58K
Henderson Far East Income Ltd
LSE:HFEL
UK GBX59.12 Million
Henderson Smaller Cos Inv Tst
LSE:HSL
UK GBX71.76 Million
Charan Insurance Public Company Limited
BK:CHARAN
Thailand ฿321.06 Million
GENINCODE PLC LS -01
F:9PL
Germany €1.56 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Carmat's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALCAR market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.70 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.83 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Carmat's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Carmat (2009–2024)

The table below shows the annual total liabilities of Carmat from 2009 to 2024.

Year Total Liabilities Change
2024-12-31 €93.56 Million
≈ $109.38 Million
-3.38%
2023-12-31 €96.83 Million
≈ $113.21 Million
+16.29%
2022-12-31 €83.27 Million
≈ $97.35 Million
+0.77%
2021-12-31 €82.63 Million
≈ $96.60 Million
+58.85%
2020-12-31 €52.02 Million
≈ $60.81 Million
+29.37%
2019-12-31 €40.21 Million
≈ $47.01 Million
+146.81%
2018-12-31 €16.29 Million
≈ $19.05 Million
+28.87%
2017-12-31 €12.64 Million
≈ $14.78 Million
+46.98%
2016-12-31 €8.60 Million
≈ $10.06 Million
+18.69%
2015-12-31 €7.25 Million
≈ $8.47 Million
+15.43%
2014-12-31 €6.28 Million
≈ $7.34 Million
-57.46%
2013-12-31 €14.76 Million
≈ $17.25 Million
+51.25%
2012-12-31 €9.76 Million
≈ $11.41 Million
-7.40%
2011-12-31 €10.54 Million
≈ $12.32 Million
+89.66%
2010-12-31 €5.55 Million
≈ $6.49 Million
+180.91%
2009-12-31 €1.98 Million
≈ $2.31 Million
--

About Carmat

PA:ALCAR France Medical Devices
Market Cap
$7.44 Million
€6.36 Million EUR
Market Cap Rank
#28059 Global
#505 in France
Share Price
€0.10
Change (1 day)
+0.00%
52-Week Range
€0.10 - €0.62
All Time High
€53.45
About

Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.